Literature DB >> 24783465

Implementation of transmural disease management in patients admitted with advanced heart failure.

Jürgen Duchenne, Frederik H Verbrugge, Matthias Dupont, Jan Vercammen, Linda Jacobs, Lars Grieten, Pieter Vandervoort, Wilfried Mullens.   

Abstract

OBJECTIVE: The objective of this study was to assess the feasibility and impact on readmissions of transmural disease management across the borders of the cardiology department in patients with advanced heart failure (HF). METHODS AND
RESULTS: Consecutive patients, readmitted within one year for advanced HF by a dedicated specialist (n = 55), were followed for 22 +/- 10 months after implementation of a hospitalwide transmural disease management strategy. Participants received a tag in their electronic medical record, triggering a HF caregiver contact, with subsequent guideline-recommended, protocol-driven care on each cardiac or non-cardiac hospitalization as well as outpatient evaluation. Upon transition to outpatient follow-up, patients were instructed to call the HF caregiver with any question at low threshold. Readmission rates were prospectively collected. Despite receiving adequate treatment with neurohumoral blockers, patients (71 +/- 11 years; ejection fraction 35 +/- 13%) had spent 4% (27%) of the year preceding study inclusion in hospital, with 73% admitted once, 20% twice, and 7% more than twice for acute decompensated HF (ADHF). During the study, patients were exposed to 6 +/- 4 dedicated HF caregiver contacts. Participation in remote device monitoring increased from 31% to 92%, with 1 (0-3) additional phone contacts per patient-year of follow-up in this subgroup (n = 24). All-cause mortality and readmission rates for ADHF were 10% and 25% after one year, and 19% and 39% after 2 years, respectively. Follow-up time spent in hospital decreased significantly to 2% (16%) (P value = 0.047).
CONCLUSIONS: Follow-up of advanced HF patients through transmural disease management is feasible and associated with favourable clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24783465     DOI: 10.1080/ac.69.2.3017295

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  4 in total

Review 1.  Current Approach to Decongestive Therapy in Acute Heart Failure.

Authors:  Pieter Martens; Petra Nijst; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2015-12

2.  Bioimpedance Alerts from Cardiovascular Implantable Electronic Devices: Observational Study of Diagnostic Relevance and Clinical Outcomes.

Authors:  Christophe Jp Smeets; Julie Vranken; Jo Van der Auwera; Frederik H Verbrugge; Wilfried Mullens; Matthias Dupont; Lars Grieten; Hélène De Cannière; Dorien Lanssens; Thijs Vandenberk; Valerie Storms; Inge M Thijs; Pieter M Vandervoort
Journal:  J Med Internet Res       Date:  2017-11-23       Impact factor: 5.428

3.  Improving kNowledge Transfer to Efficaciously RAise the level of Contemporary Treatment in Heart Failure (INTERACT-in-HF): Study protocol of a mixed methods study.

Authors:  Karolien Baldewijns; Sema Bektas; Josiane Boyne; Carla Rohde; Lieven De Maesschalck; Leentje De Bleser; Vincent Brandenburg; Christian Knackstedt; Aleidis Devillé; Sandra Sanders-Van Wijk; Hans-Peter Brunner La Rocca
Journal:  Int J Care Coord       Date:  2017-08-20

4.  A Novel Intelligent Two-Way Communication System for Remote Heart Failure Medication Uptitration (the CardioCoach Study): Randomized Controlled Feasibility Trial.

Authors:  Christophe Jp Smeets; Valerie Storms; Pieter M Vandervoort; Pauline Dreesen; Julie Vranken; Marita Houbrechts; Hanne Goris; Lars Grieten; Paul Dendale
Journal:  JMIR Cardio       Date:  2018-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.